新型核苷类似物治疗出血热病毒感染。
New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections.
机构信息
Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
出版信息
Chem Asian J. 2019 Nov 18;14(22):3962-3968. doi: 10.1002/asia.201900841. Epub 2019 Aug 7.
Abstract
Eight different compounds, all nucleoside analogues, could presently be considered as potential drug candidates for the treatment of Ebola virus (EBOV) and/or other hemorrhagic fever virus (HFV) infections. They can be considered as either (i) adenine analogues (3-deazaneplanocin A, galidesivir, GS-6620 and remdesivir) or (ii) guanine analogues containing the carboxamide entity (ribavirin, EICAR, pyrazofurin and favipiravir). All eight owe their mechanism of action to hydrogen bonded base pairing with either (i) uracil or (ii) cytosine. Four out of the eight compounds (galidesivir, GS-6620, remdesivir and pyrazofurin) are C-nucleosides, and two of them (GS-6620, remdesivir) also contain a phosphoramidate part. The C-nucleoside and phosphoramidate (and for the adenine analogues the 1'-cyano group as well) may be considered as essential attributes for their antiviral activity.
摘要
目前，有八种不同的化合物，均为核苷类似物，可以被视为治疗埃博拉病毒（EBOV）和/或其他出血热病毒（HFV）感染的潜在候选药物。这些化合物可被分为两类：（i）腺嘌呤类似物（3-去氮杂环胞苷、加洛韦、GS-6620 和瑞德西韦）或（ii）含羧酰胺基的鸟嘌呤类似物（利巴韦林、EICAR、吡唑呋喃和法匹拉韦）。这八种化合物的作用机制均为通过氢键与尿嘧啶或胞嘧啶碱基配对。这八种化合物中有四种（加洛韦、GS-6620、瑞德西韦和吡唑呋喃）为 C-核苷，其中两种（GS-6620、瑞德西韦）还含有磷酰胺酯部分。C-核苷和磷酰胺酯（以及腺嘌呤类似物的 1'-氰基）可被视为其抗病毒活性的必要属性。
相似文献
1
New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections.
Chem Asian J. 2019 Nov 18;14(22):3962-3968. doi: 10.1002/asia.201900841. Epub 2019 Aug 7.
2
Curious (Old and New) Antiviral Nucleoside Analogues with Intriguing Therapeutic Potential.
Curr Med Chem. 2015;22(34):3866-80. doi: 10.2174/0929867322666150625094705.
3
Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses.
Antiviral Res. 2016 Feb;126:62-8. doi: 10.1016/j.antiviral.2015.12.006. Epub 2015 Dec 19.
4
Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
J Nanosci Nanotechnol. 2020 Dec 1;20(12):7311-7323. doi: 10.1166/jnn.2020.18955.
5
Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus.
Antiviral Res. 2018 Mar;151:50-54. doi: 10.1016/j.antiviral.2017.12.020. Epub 2017 Dec 28.
6
C-Nucleosides To Be Revisited.
J Med Chem. 2016 Mar 24;59(6):2301-11. doi: 10.1021/acs.jmedchem.5b01157. Epub 2015 Oct 29.
7
Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01305-16. Print 2017 Jan.
8
Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.
Clin Pharmacokinet. 2016 Aug;55(8):907-23. doi: 10.1007/s40262-015-0364-1.
9
A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
EMBO Mol Med. 2021 Jan 11;13(1):e13105. doi: 10.15252/emmm.202013105. Epub 2020 Nov 3.
10
New nucleoside analogues for chronic hepatitis B.
Acta Gastroenterol Belg. 2000 Apr-Jun;63(2):191-3.
引用本文的文献
1
Dysregulated glycerophospholipid metabolism in amygdala may mediate favipiravir-induced anxiety-like behaviors in mice.
Front Pharmacol. 2025 Mar 4;16:1491150. doi: 10.3389/fphar.2025.1491150. eCollection 2025.
2
Advancements in the development of antivirals against SARS-Coronavirus.
Front Cell Infect Microbiol. 2025 Jan 23;15:1520811. doi: 10.3389/fcimb.2025.1520811. eCollection 2025.
3
Innovative anti-proliferative effect of the antiviral favipiravir against MCF-7 breast cancer cells using green nanoemulsion and eco-friendly assessment tools.
Sci Rep. 2024 Nov 14;14(1):27939. doi: 10.1038/s41598-024-78422-2.
4
Metabolic RNA labeling in non-engineered cells following spontaneous uptake of fluorescent nucleoside phosphate analogues.
Nucleic Acids Res. 2024 Sep 23;52(17):10102-10118. doi: 10.1093/nar/gkae722.
5
Immunization against Medically Important Human Coronaviruses of Public Health Concern.
Can J Infect Dis Med Microbiol. 2024 Jun 8;2024:9952803. doi: 10.1155/2024/9952803. eCollection 2024.
6
POxload: Machine Learning Estimates Drug Loadings of Polymeric Micelles.
Mol Pharm. 2024 Jul 1;21(7):3356-3374. doi: 10.1021/acs.molpharmaceut.4c00086. Epub 2024 May 28.
7
Molecular modeling of some commercially available antiviral drugs and their derivatives against SARS-CoV-2 infection.
Narra J. 2024 Apr;4(1):e319. doi: 10.52225/narra.v4i1.319. Epub 2024 Apr 30.
8
Marine Brown Algae-Derived Compounds as Potential Inhibitors of Japanese Encephalitis Virus RNA-Dependent RNA Polymerase.
Mar Drugs. 2024 Feb 17;22(2):92. doi: 10.3390/md22020092.
9
Favipiravir, an antiviral drug, in combination with tamoxifen exerts synergistic effect in tamoxifen-resistant breast cancer cells via hTERT inhibition.
Sci Rep. 2024 Jan 22;14(1):1844. doi: 10.1038/s41598-024-51977-w.
10
1-Sulfonyl-3-amino-1-1,2,4-triazoles as Yellow Fever Virus Inhibitors: Synthesis and Structure-Activity Relationship.
ACS Omega. 2023 Nov 1;8(45):42951-42965. doi: 10.1021/acsomega.3c06106. eCollection 2023 Nov 14.
本文引用的文献
1
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir.
Viruses. 2019 Apr 4;11(4):326. doi: 10.3390/v11040326.
2
Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters.
Antiviral Res. 2018 Aug;156:38-45. doi: 10.1016/j.antiviral.2018.05.013. Epub 2018 Jun 1.
3
Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.
PLoS Med. 2018 Mar 27;15(3):e1002535. doi: 10.1371/journal.pmed.1002535. eCollection 2018 Mar.
4
Favipiravir as a potential countermeasure against neglected and emerging RNA viruses.
Antiviral Res. 2018 May;153:85-94. doi: 10.1016/j.antiviral.2018.03.003. Epub 2018 Mar 7.
5
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
mBio. 2018 Mar 6;9(2):e00221-18. doi: 10.1128/mBio.00221-18.
6
Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase.
PLoS Pathog. 2018 Feb 9;14(2):e1006889. doi: 10.1371/journal.ppat.1006889. eCollection 2018 Feb.
7
Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus.
Antiviral Res. 2018 Mar;151:97-104. doi: 10.1016/j.antiviral.2017.12.021. Epub 2017 Dec 28.
8
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463. doi: 10.2183/pjab.93.027.
9
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.
Sci Transl Med. 2017 Jun 28;9(396). doi: 10.1126/scitranslmed.aal3653.
10
Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses.
Antiviral Res. 2017 Jun;142:63-67. doi: 10.1016/j.antiviral.2017.03.012. Epub 2017 Mar 21.
Zotero 插件